Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The firm is not a momentum investor and avoids companies with uncertain future earnings and high valuations. The firm invests for the long-term and remains curious about new companies. As of December 31, 2024, the Global Equity strategy had USD 25.7 billion in total assets under management. In addition, please check the fund’s top five holdings to know its best picks in 2024.
In its fourth quarter 2024 investor letter, Generation Global Equity Strategy emphasized stocks such as Becton, Dickinson and Company (NYSE:BDX). Becton, Dickinson and Company (NYSE:BDX) is a medical device company that develops and manufactures medical supplies, devices, laboratory equipment, and diagnostic products. The one-month return of Becton, Dickinson and Company (NYSE:BDX) was -3.46%, and its shares lost 9.98% of their value over the last 52 weeks. On April 3, 2025, Becton, Dickinson and Company (NYSE:BDX) stock closed at $221.59 per share with a market capitalization of $63.626 billion.
Generation Global Equity Strategy stated the following regarding Becton, Dickinson and Company (NYSE:BDX) in its Q4 2024 investor letter:
“Becton, Dickinson and Company (NYSE:BDX) is a US-based medical device company with USD 20 billion in revenue. A staple in our portfolio for 18 years, BD produces essential consumables like syringes and infusion systems. While not a flashy growth story, BD has delivered consistent 5% revenue growth per decade since the 1990s.
The company has a commanding 60% market share in its segments, providing a stable foundation for future revenue growth. Moreover, BD is improving its margins after navigating supply chain disruptions and COVID-related volatility. With its ‘pricing muscle memory’ now firmly in place, we expect steady earnings growth.
BD’s recent underperformance, combined with market apathy toward steady growers, creates an attractive entry point from a valuation perspective. Challenges include inflationary pressures and a mixed history with large acquisitions, but we are confident in BD’s ability to deliver strong, long term returns.”
A surgeon performing a procedure in an operating room using a medical device supplied by the company.
Becton, Dickinson and Company (NYSE:BDX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 56 hedge fund portfolios held Becton, Dickinson and Company (NYSE:BDX) at the end of the fourth quarter compared to 52 in the third quarter. While we acknowledge the potential of Becton, Dickinson and Company (NYSE:BDX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
We covered Becton, Dickinson and Company (NYSE:BDX) in another article, where we shared River Road Large Cap Value Select Fund’s views on the company. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.